文献速递乳腺癌放疗

21基因复发评分可预测年龄≥70岁T1N0 ER/PR+HER2-乳腺癌患者接受保乳手术和内分泌治疗后放疗的预后获益

21-Gene recurrence score predictive for prognostic benefit of radiotherapy in patients age ≥ 70 with T1N0 ER/PR + HER2- breast cancer treated with breast conserving surgery and endocrine therapy.
PubMed 文献 · Radiother Oncol · 2022-06-27

基于国家癌症数据库(NCDB)2004-2017年的回顾性研究,纳入11,891例年龄≥70岁pT1N0 ER+/PR+HER2-乳腺癌患者,均接受保乳手术和内分泌治疗。按复发评分(RS)分层后经倾向性评分匹配分析,低风险组(RS 1-10)放疗与未放疗的5年总生存无显著差异(91% vs 89%,p=0.605),而中高风险组合并组(RS 11-99)放疗组5年总生存优于未放疗组(91% vs 87%,p=0.003)。作者建议对该老年亚组评估RS,当RS≥11时考虑放疗,但需前瞻性验证。

要点

  • 低风险组(RS 1-10)放疗与未放疗的5年OS无显著差异(91% vs 89%,p=0.605)。
  • 中高风险组合并组(RS 11-99)放疗组5年OS优于未放疗组(91% vs 87%,p=0.003)。
  • 作者建议对该老年亚组评估RS,当RS≥11时考虑放疗,但需前瞻性验证。

核心结论

  • 在年龄≥70岁接受保乳手术和内分泌治疗的pT1N0 ER+/PR+HER2-乳腺癌患者中,中高风险复发评分(RS 11-99)患者接受放疗有总生存获益,而低风险复发评分(RS 1-10)患者无总生存获益。
  • 作者建议对该老年亚组评估复发评分,当RS≥11时考虑放疗,但需前瞻性验证。

研究设计与样本

  • 回顾性研究,查询国家癌症数据库(NCDB)2004-2017年数据,纳入年龄≥70岁pT1N0 ER+/PR+HER2-乳腺癌接受保乳手术和内分泌治疗的患者。
  • 共纳入11,891例患者,按复发评分分层:低风险组(RS 1-10)3,364例,中风险组(RS 11-25)7,305例,高风险组(RS 26-99)1,222例。
  • 采用倾向性评分匹配(PSM)创建1:1匹配的放疗组与未放疗组;因高风险组单独无法有效进行PSM,将中风险组和高风险组合并(IRHR)后匹配。
  • 采用Kaplan-Meier分析评估总生存(OS),采用单变量(UVA)和多变量(MVA)Cox比例风险分析识别OS的预后因素。

主要发现

  • 全部患者中79%接受放疗:低风险组77%,中风险组79%,高风险组85%。
  • 倾向性评分匹配后,低风险组5年OS放疗组91% vs 未放疗组89%(p=0.605)。
  • 倾向性评分匹配后,中高风险组合并组5年OS放疗组91% vs 未放疗组87%(p=0.003)。
  • 低风险组多变量分析中,放疗对OS改善无预测作用(p=0.727)。
  • 中高风险组合并组多变量分析中,放疗是OS的正面预后因素(p=0.010)。

关键数值与推荐

  • 复发评分分层:低风险=1-10,中风险=11-25,高风险=26-99。
  • 作者建议对该老年亚组评估复发评分,当RS≥11时考虑放疗,但需前瞻性验证。

临床怎么用

  • 作者建议对年龄≥70岁接受保乳手术和内分泌治疗的pT1N0 ER+/PR+HER2-乳腺癌患者评估复发评分,当RS≥11时考虑放疗,但需前瞻性验证。

局限性

  • 原文为回顾性研究。
  • 作者指出需前瞻性验证(Pending prospective evaluation)。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: Based on the results of the Cancer and Leukemia Group B (CALGB) 9343 trial, patients age ≥70 with T1N0 hormone receptor positive (ER/PR+), human epidermal growth factor receptor-2 negative (HER2-) breast cancer who are treated with breast conserving surgery (BCS) and endocrine therapy (ET) are candidates for omission of radiotherapy (RT). Because the CALGB 9343 trial did not stratify based on recurrence score (RS) test (Oncotype Dx), we conducted the present retrospective study to determine whether RS is predictive of who may benefit from RT following BCS in this cohort. MATERIALS AND METHODS: The National Cancer Database (NCDB) was queried (2004-2017) for patients age ≥ 70 with pT1N0 ER+/PR + HER2- breast cancer treated with BCS and ET. Patients were stratified based on their RS (low risk [LR] = 1-10, intermediate risk [IR] = 11-25, high risk [HR] = 26-99). Propensity score matching (PSM) created 1:1 matched cohorts of patients who received radiotherapy and those who did not. Kaplan-Meier analysis evaluated overall survival (OS). Univariable (UVA) and multivariable (MVA) Cox proportional hazard analyses identified clinical and treatment factors prognostic for OS. RESULTS: A total of 11,891 patients met the selection criteria: 3364 in the LR cohort, 7305 in the IR cohort, and 1222 in the HR cohort. A total of 79 % received RT: 77 % in the LR cohort, 79 % in the IR cohort, and 85 % in the HR cohort. Because PSM could not be efficiently performed in the HR cohort alone, the IR and HR cohort were merged (IRHR) for matching. After PSM, the 5-year OS in the LR cohort was 91 % for those who received RT and 89 % for those who did not (p = 0.605). In the IRHR cohort, the 5-year OS was 91 % for those who received RT and 87 % for those who did not (p = 0.003). On MVA in the LR cohort, RT (p = 0.727) was not predictive of improved OS. On MVA in the IRHR cohort, RT (p = 0.010) was a positive prognostic factor for OS. CONCLUSION: In this older cohort of patients, there is an OS benefit with the use of RT in patients with IRHR RS but not in patients with LR RS. Pending prospective evaluation, assessment of RS in this older subset of patients is recommended with consideration of RT when RS is ≥11.

来源:Radiother Oncol,查看原文。版权归原作者所有。

引用

  1. Chevli N, Haque W, Tran KT, et al. 21-Gene recurrence score predictive for prognostic benefit of radiotherapy in patients age ≥ 70 with T1N0 ER/PR + HER2- breast cancer treated with breast conserving surgery and endocrine therapy. Radiother Oncol. 2022. PMID: 35772577. doi:10.1016/j.radonc.2022.06.013

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。